|
|
|
A novel strategy for regulating a protein important in development is described in Nature this week. Michael T. Longaker and colleagues report that, in mice, glycogen synthase kinase-3beta (GSK-3beta) can be artificially controlled from within the mother's uterus, in a reversible and time-controlled manner.
GSK-3beta plays an integral part in a variety of biological processes, although its specific developmental roles remain unclear. In the present study the authors used an existing chemically regulated form of the GSK-3beta gene, whereby expression of the GSK-3beta protein is controlled by the presence or absence of the drug rapamycin. Using this approach combined with conventional mutant analysis they defined a specific requirement for GSK-3beta in midline development: mice that did not express the protein had cleft palate, incomplete fusion of the ribs and a split sternum. In addition, the authors were able to rescue some of the developmental defects using maternal rapamycin treatment to restore internal GSK-3beta activity during two distinct windows of gestation. They propose that their studies provide an improved method for defining the timing and level of protein expression during development, a detailed knowledge of which is essential for rescuing developmental defects. Author contact: Michael T. Longaker (Stanford University Medical Center, CA, USA)
E-mail: longaker@stanford.edu (C) Nature press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|